Back to News
Market Impact: 0.35
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
Source: zacks.com
Healthcare & BiotechCompany Fundamentals
GKOS expanded its retinal pipeline through a licensing deal for RO-104 and obtained exclusive rights to the RevMod platform. Shares declined 6.3% following the news.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.15
More News
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- MTY Food Group Inc Profit Retreats In Q3
- Why is T-Mobile stock tumbling today?
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings